IPF is driven by senescent alveolar type II epithelial cells that promote fibrotic remodeling via TGF-β-rich SASP. Two published D+Q trials in IPF patients show consistent results: senescent cell biomarker reduction in skin and peripheral blood, and clinically meaningful improvement in 6-minute walk distance and other physical function metrics.

Can D+Q reverse established lung fibrosis?

Current evidence shows reduction in senescent cell burden and improvement in functional capacity, but not structural reversal of established fibrosis. The goal is to slow or halt progression, not reverse pre-existing scarring.

Is D+Q a standard of care for IPF?

No. D+Q is an investigational treatment for IPF. Standard FDA-approved therapies (pirfenidone, nintedanib) are the primary treatment. D+Q may be added under clinical trial or compassionate use protocols.